With the supply of Lilly’s diabetes and obesity medicines Mounjaro and Zepbound stabilized, the company is planning to initiate “demand stimulating” activities for the two tirzepatide brands, including direct-to-consumer advertising in November.
Lilly Plans Mounjaro/Zepbound DTC Ads To Stoke Brand Awareness
Third quarter sales of the diabetes and obesity drug tirzepatide surpassed $4bn but missed analyst consensus estimates, triggering questions from investors.
More from Earnings
More from Therapy Areas
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.